|
Press Room
2007 Press Releases
TSX:V - IXS
NASD OTC:BB: IXSBF
October 03, 2007
InNexus CEO to Present at the 15th Anniversary BioPartnering Europe Conference
British Columbia, Canada - September 18, 2007 - InNexus Biotechnology Inc. (OTCBB: IXSBF, TSX: IXS.V), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, , is pleased to announce that Jeff Morhet, Chairman and CEO, will give an Open House Podium Presentation at the 15th Anniversary BioPartnering Europe Conference. The conference will be held on Tuesday, October 9th at 2:00 pm in the Abbey Room West at the Queen Elizabeth II Conference Centre in London, UK. Mr. Morhet will introduce the company and its Dynamic Cross Linking (DXL?) technology, alliances and recent clinical developments.
About BioPartnering Europe
BioPartnering Europe (BPE) was first held in London in 1993 as a partnership between the U.S. Commercial Service and Technology Vision Group LLC to bring about closer ties between American and European biotechnology companies. From the beginning, BPE has attracted the support of leading pharmaceutical, biotechnology, financial, and service companies who have all contributed to making this one of the leading independent partnering events in the world. For more information, please visit the website, techvision.com/bpe/
.
About InNexus
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL™ technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.
Forward-Looking Statements
This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding future drug development activities or anticipated products, anticipated future revenues, benefits or advantages, and the future plans and objectives of the Company, that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.
Contact
InNexus Biotechnology Inc.
Wade Brooksby, CFO
480-862-7500
The Investor Relations Group
Investor Relations:
Christine Berni/Joe Triunfo, 212-825-3210
cberni@investorrelationsgroup.com
jtriunfo@investorrelationsgroup.com
Media:
Janet Vasquez/ Michaela Heller, 212-825-3210
jvasquez@investorrelationsgroup.com
mheller@investorrelationsgroup.com
|
|
|
